Petersen Jonas, Ingemann Johansen Valdemar Brimnes, Clemmensen Christoffer
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Cell Metab. 2025 Mar 4;37(3):790-790.e1. doi: 10.1016/j.cmet.2025.02.006.
Advances in the understanding of homeostatic regulation of body weight and the neurobiology of appetite, combined with innovations in medicinal chemistry, have paved the way for safe and effective weight loss medications. Long-acting GLP-1 receptor agonists have revolutionized obesity treatment, and, together with emerging GLP-1-based multi-agonists and combination therapies, offer significant potential to combat cardiometabolic diseases and a range of other chronic health challenges. To view this SnapShot, open or download the PDF.
对体重稳态调节和食欲神经生物学理解的进展，再加上药物化学的创新，为安全有效的减肥药物铺平了道路。长效胰高血糖素样肽-1（GLP-1）受体激动剂彻底改变了肥胖症治疗方式，并且与新兴的基于GLP-1的多靶点激动剂和联合疗法一起，为对抗心脏代谢疾病及一系列其他慢性健康挑战提供了巨大潜力。要查看此快照，请打开或下载PDF文件。
